{"pmid":32426001,"pmcid":"PMC7229928","title":"[Colchicine: a potential therapeutic tool against COVID-19. Experience of 5 patients].","text":["[Colchicine: a potential therapeutic tool against COVID-19. Experience of 5 patients].","COVID-19 is a newly emerged disease that has become a global public health challenge. Due to a lack of knowledge about the virus, a significant number of potential targets for using a particular drug have been proposed. Five cases with a clinical history of biopolymers in the gluteal region that developed iatrogenic allogenosis (IA) are presented here. The 5 cases were put under colchicine treatment for IA crisis and had non-specific symptoms (headache, cough without dyspnoea, and arthralgias) with a positive SARS-CoV-2 test. Their close contacts had mild to severe symptoms and three of them died. In the SARS-CoV-2 infection different inflammatory pathways are altered where colchicine reduces cytokine levels as well as the activation of macrophages, neutrophils, and the inflammasome. The possible mechanisms that colchicine may use to prevent acute respiratory distress syndrome (ARDS) in patients with COVID-19 infection are also reviewed in this article.","Reumatol Clin","Montealegre-Gomez, Giovanni","Garavito, Edgar","Gomez-Lopez, Arley","Rojas-Villarraga, Adriana","Parra-Medina, Rafael","32426001"],"abstract":["COVID-19 is a newly emerged disease that has become a global public health challenge. Due to a lack of knowledge about the virus, a significant number of potential targets for using a particular drug have been proposed. Five cases with a clinical history of biopolymers in the gluteal region that developed iatrogenic allogenosis (IA) are presented here. The 5 cases were put under colchicine treatment for IA crisis and had non-specific symptoms (headache, cough without dyspnoea, and arthralgias) with a positive SARS-CoV-2 test. Their close contacts had mild to severe symptoms and three of them died. In the SARS-CoV-2 infection different inflammatory pathways are altered where colchicine reduces cytokine levels as well as the activation of macrophages, neutrophils, and the inflammasome. The possible mechanisms that colchicine may use to prevent acute respiratory distress syndrome (ARDS) in patients with COVID-19 infection are also reviewed in this article."],"journal":"Reumatol Clin","authors":["Montealegre-Gomez, Giovanni","Garavito, Edgar","Gomez-Lopez, Arley","Rojas-Villarraga, Adriana","Parra-Medina, Rafael"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32426001","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.reuma.2020.05.001","keywords":["ards","covid-19","colchicine","inflammasome","sars-cov-2"],"locations":["Colchicine"],"e_drugs":["Colchicine"],"topics":["Treatment"],"weight":1,"_version_":1667352728732434432,"score":9.490897,"similar":[{"pmid":32380315,"pmcid":"PMC7198406","title":"Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis.","text":["Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis.","BACKGROUND: Some disease-modifying agents commonly used to treat patients with rheumatic diseases/autoimmune disorders, such as hydroxychloroquine and colchicine, are under investigation as potential therapies for the \"coronavirus disease 2019\" (COVID-19). However, the role of such agents as prophylactic tools is still not clear. METHODS: This is a retrospective study based on a large healthcare computerized database including all patients that were screened for the \"Severe Acute Respiratory Syndrome Coronavirus type 2\" (SARS-CoV-2) in the study period from February 23rd 2020 to March 31st 2020. A comparison was conducted between subjects tested positive for SARS-CoV-2 and those found negative in terms of rate of administration of hydroxychloroquine/colchicine therapy. RESULTS: An overall sample of 14,520 subjects were screened for SARS-CoV-2 infection and 1317 resulted positive. No significant difference was found in terms of rates of usage of hydroxychloroquine or colchicine between those who were found positive for SARS-CoV-2 and those who were found negative (0.23% versus 0.25% for hydroxychloroquine, and 0.53% versus 0.48% for colchicine, respectively). CONCLUSION: These findings raise doubts regarding the protective role of these medications in the battle against SARS-CoV-2 infection.","Autoimmun Rev","Gendelman, Omer","Amital, Howard","Bragazzi, Nicola Luigi","Watad, Abdulla","Chodick, Gabriel","32380315"],"abstract":["BACKGROUND: Some disease-modifying agents commonly used to treat patients with rheumatic diseases/autoimmune disorders, such as hydroxychloroquine and colchicine, are under investigation as potential therapies for the \"coronavirus disease 2019\" (COVID-19). However, the role of such agents as prophylactic tools is still not clear. METHODS: This is a retrospective study based on a large healthcare computerized database including all patients that were screened for the \"Severe Acute Respiratory Syndrome Coronavirus type 2\" (SARS-CoV-2) in the study period from February 23rd 2020 to March 31st 2020. A comparison was conducted between subjects tested positive for SARS-CoV-2 and those found negative in terms of rate of administration of hydroxychloroquine/colchicine therapy. RESULTS: An overall sample of 14,520 subjects were screened for SARS-CoV-2 infection and 1317 resulted positive. No significant difference was found in terms of rates of usage of hydroxychloroquine or colchicine between those who were found positive for SARS-CoV-2 and those who were found negative (0.23% versus 0.25% for hydroxychloroquine, and 0.53% versus 0.48% for colchicine, respectively). CONCLUSION: These findings raise doubts regarding the protective role of these medications in the battle against SARS-CoV-2 infection."],"journal":"Autoimmun Rev","authors":["Gendelman, Omer","Amital, Howard","Bragazzi, Nicola Luigi","Watad, Abdulla","Chodick, Gabriel"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32380315","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.autrev.2020.102566","keywords":["autoimmunity","covid-19","colchicine","hydroxychloroquine","rheumatic disease","sars-cov-2"],"e_drugs":["Colchicine","Hydroxychloroquine"],"topics":["Treatment"],"weight":1,"_version_":1666597097430843392,"score":248.96811},{"pmid":32251729,"pmcid":"PMC7194546","title":"The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design.","text":["The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design.","OBJECTIVE: Colchicine has been utilized safely in a variety of cardiovascular clinical conditions. Among its potential mechanisms of action is the non-selective inhibition of NLRP3 inflammasome which is thought to be a major pathophysiologic component in the clinical course of patients with COVID-19. GRECCO-19 will be a prospective, randomized, open-labeled, controlled study to assess the effects of colchicine in COVID-19 complications prevention. METHODS: Patients with laboratory confirmed SARS-CoV-2 infection (under RT PCR) and clinical picture that involves temperature >37.5 oC and at least two out of the: i. sustained coughing, ii. sustained throat pain, iii. Anosmia and/or ageusia, iv. fatigue/tiredness, v. PaO2<95 mmHg will be included. Patients will be randomised (1:1) in colchicine or control group. RESULTS: Trial results will be disseminated through peer-reviewed publications and conference presentations. CONCLUSION: GRECCO-19 trial aims to identify whether colchicine may positively intervene in the clinical course of COVID-19. (ClinicalTrials.gov Identifier: NCT04326790).","Hellenic J Cardiol","Deftereos, Spyridon G","Siasos, Gerasimos","Giannopoulos, Georgios","Vrachatis, Dimitrios A","Angelidis, Christos","Giotaki, Sotiria G","Gargalianos, Panagiotis","Giamarellou, Helen","Gogos, Charalampos","Daikos, Georgios","Lazanas, Marios","Lagiou, Pagona","Saroglou, Georgios","Sipsas, Nikolaos","Tsiodras, Sotirios","Chatzigeorgiou, Dimitrios","Moussas, Nikolaos","Kotanidou, Anastasia","Koulouris, Nikolaos","Oikonomou, Evangelos","Kaoukis, Andreas","Kossyvakis, Charalampos","Raisakis, Konstantinos","Fountoulaki, Katerina","Comis, Mihalis","Tsiachris, Dimitrios","Sarri, Eleni","Theodorakis, Andreas","Martinez-Dolz, Luis","Sanz-Sanchez, Jorge","Reimers, Bernhard","Stefanini, Giulio G","Cleman, Michael","Filippou, Dimitrios","Olympios, Christoforos D","Pyrgakis, Vlasios N","Goudevenos, John","Hahalis, George","Kolettis, Theofilos M","Iliodromitis, Efstathios","Tousoulis, Dimitrios","Stefanadis, Christodoulos","32251729"],"abstract":["OBJECTIVE: Colchicine has been utilized safely in a variety of cardiovascular clinical conditions. Among its potential mechanisms of action is the non-selective inhibition of NLRP3 inflammasome which is thought to be a major pathophysiologic component in the clinical course of patients with COVID-19. GRECCO-19 will be a prospective, randomized, open-labeled, controlled study to assess the effects of colchicine in COVID-19 complications prevention. METHODS: Patients with laboratory confirmed SARS-CoV-2 infection (under RT PCR) and clinical picture that involves temperature >37.5 oC and at least two out of the: i. sustained coughing, ii. sustained throat pain, iii. Anosmia and/or ageusia, iv. fatigue/tiredness, v. PaO2<95 mmHg will be included. Patients will be randomised (1:1) in colchicine or control group. RESULTS: Trial results will be disseminated through peer-reviewed publications and conference presentations. CONCLUSION: GRECCO-19 trial aims to identify whether colchicine may positively intervene in the clinical course of COVID-19. (ClinicalTrials.gov Identifier: NCT04326790)."],"journal":"Hellenic J Cardiol","authors":["Deftereos, Spyridon G","Siasos, Gerasimos","Giannopoulos, Georgios","Vrachatis, Dimitrios A","Angelidis, Christos","Giotaki, Sotiria G","Gargalianos, Panagiotis","Giamarellou, Helen","Gogos, Charalampos","Daikos, Georgios","Lazanas, Marios","Lagiou, Pagona","Saroglou, Georgios","Sipsas, Nikolaos","Tsiodras, Sotirios","Chatzigeorgiou, Dimitrios","Moussas, Nikolaos","Kotanidou, Anastasia","Koulouris, Nikolaos","Oikonomou, Evangelos","Kaoukis, Andreas","Kossyvakis, Charalampos","Raisakis, Konstantinos","Fountoulaki, Katerina","Comis, Mihalis","Tsiachris, Dimitrios","Sarri, Eleni","Theodorakis, Andreas","Martinez-Dolz, Luis","Sanz-Sanchez, Jorge","Reimers, Bernhard","Stefanini, Giulio G","Cleman, Michael","Filippou, Dimitrios","Olympios, Christoforos D","Pyrgakis, Vlasios N","Goudevenos, John","Hahalis, George","Kolettis, Theofilos M","Iliodromitis, Efstathios","Tousoulis, Dimitrios","Stefanadis, Christodoulos"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251729","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.hjc.2020.03.002","keywords":["covid","crp","cardiac","complications","troponin"],"locations":["Colchicine","colchicine","Greek"],"countries":["Greece"],"countries_codes":["GRC|Greece"],"e_drugs":["Colchicine"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138490987872260,"score":236.88205},{"pmid":32503620,"title":"Adding Colchicine to the Antiretroviral Medication - Lopinavir/Ritonavir (Kaletra) in Hospitalized Patients with Non-Severe Covid-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomized Controlled Trial.","text":["Adding Colchicine to the Antiretroviral Medication - Lopinavir/Ritonavir (Kaletra) in Hospitalized Patients with Non-Severe Covid-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomized Controlled Trial.","OBJECTIVES: Colchicine is a well-known drug, which has been used for years to treat a wide range of rheumatic and inflammatory disorders. It helps break the cycle of inflammation through diverse mechanisms including reducing Intereukin-6, Interleukin-8, Tumour Necrosis Factor-alpha besides controlling oxidative stress pathways which all are important and pathologic components in the clinical course and outcome of patients infected with COVID-19. This study aims to assess the anti-inflammatory effects of colchicine in non-severe hospitalized COVID-19 patients. TRIAL DESIGN: Prospective, randomized (1:1 ratio), double blind study with parallel group design. PARTICIPANTS: Hospitalized patients with positive nasopharyngeal swab for COVID-19 infection (RT -PCR) and lung Computed tomography scan involvement compatible with COVID-19 pneumonia. The patients are not severely hypoxic, do not need intubation or invasive oxygenation. EXCLUSION CRITERIA: known hypersensitivity to colchicine; known hepatic failure; estimated glomerular filtration rate (eGFR)<30 ml/min/1.73m(2) (by the CKD-EPI Creatinine Equation for Glomerular Filtration Rate (GFR) which estimates GFR based on serum creatinine. ; kidney transplant recipients, using Digoxin, QTc >450 msec. Participants will be recruited from inpatients at Labbafinejad Meidcal Center , Tehran, Iran. INTERVENTION AND COMPARATOR: Eligible enrolled patients will be randomized into two groups. Group A will receive the antiretroviral Lopinavir/Ritonavir (Kaletra) while group B will receive Lopinavir/Ritonavir (Kaletra) + Colchicine 1.5 mg loading then 0.5 mg twice daily orally. All patients in both groups will receive the same amounts of essential minerals, vitamins as antioxidants, and antibiotics. Patients of both groups will be treated under optimal treatment based on the CDC and WHO guidelines and national consensus proposed in Iran including the same dosages of Lopinavir/Ritonavir, antibiotics, trace elements and antioxidants while only in group-B patients Colchicine will be added on top of this protocol. MAIN OUTCOMES: Primary: Time for clinical improvement and lung CT score changes 14 days after treatment. Secondary: 14 days after treatment - C-Reactive Protein test x Neutrophil to Lymphocyte Ratio , Interleukin-6, malondialdehyde (MDA) levels reduction - Percentage of patients who require supplemental Oxygen - Mean hospital stay length RANDOMISATION: Patients will be allocated to each group (ratio 1:1) by using an online randomization tool: http://www.graphpad.com/quickcalcs/index.cfm BLINDING (MASKING): This will be a double-blind study in which participants and those assessing the final outcomes will be blinded to group assignment. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): Regarding the pandemic crisis and our center capacity to hospitalize confirmed COVID-19 patients, a total of 80 patients was found to be logical to be randomized into two groups of 40- patients. TRIAL STATUS: Recruitment is ongoing. Recruitment began on 20/03/2020 and the date by which the recruitment is anticipated to be completed is 30/05/2020. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04360980, registered 24/04/2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.","Trials","Dalili, Nooshin","Kashefizadeh, Alireza","Nafar, Mohsen","Poorrezagholi, Fatemeh","Firouzan, Ahmad","Samadian, Fariba","Samavat, Shiva","Ziaie, Shadi","Fatemizadeh, Somayeh","32503620"],"abstract":["OBJECTIVES: Colchicine is a well-known drug, which has been used for years to treat a wide range of rheumatic and inflammatory disorders. It helps break the cycle of inflammation through diverse mechanisms including reducing Intereukin-6, Interleukin-8, Tumour Necrosis Factor-alpha besides controlling oxidative stress pathways which all are important and pathologic components in the clinical course and outcome of patients infected with COVID-19. This study aims to assess the anti-inflammatory effects of colchicine in non-severe hospitalized COVID-19 patients. TRIAL DESIGN: Prospective, randomized (1:1 ratio), double blind study with parallel group design. PARTICIPANTS: Hospitalized patients with positive nasopharyngeal swab for COVID-19 infection (RT -PCR) and lung Computed tomography scan involvement compatible with COVID-19 pneumonia. The patients are not severely hypoxic, do not need intubation or invasive oxygenation. EXCLUSION CRITERIA: known hypersensitivity to colchicine; known hepatic failure; estimated glomerular filtration rate (eGFR)<30 ml/min/1.73m(2) (by the CKD-EPI Creatinine Equation for Glomerular Filtration Rate (GFR) which estimates GFR based on serum creatinine. ; kidney transplant recipients, using Digoxin, QTc >450 msec. Participants will be recruited from inpatients at Labbafinejad Meidcal Center , Tehran, Iran. INTERVENTION AND COMPARATOR: Eligible enrolled patients will be randomized into two groups. Group A will receive the antiretroviral Lopinavir/Ritonavir (Kaletra) while group B will receive Lopinavir/Ritonavir (Kaletra) + Colchicine 1.5 mg loading then 0.5 mg twice daily orally. All patients in both groups will receive the same amounts of essential minerals, vitamins as antioxidants, and antibiotics. Patients of both groups will be treated under optimal treatment based on the CDC and WHO guidelines and national consensus proposed in Iran including the same dosages of Lopinavir/Ritonavir, antibiotics, trace elements and antioxidants while only in group-B patients Colchicine will be added on top of this protocol. MAIN OUTCOMES: Primary: Time for clinical improvement and lung CT score changes 14 days after treatment. Secondary: 14 days after treatment - C-Reactive Protein test x Neutrophil to Lymphocyte Ratio , Interleukin-6, malondialdehyde (MDA) levels reduction - Percentage of patients who require supplemental Oxygen - Mean hospital stay length RANDOMISATION: Patients will be allocated to each group (ratio 1:1) by using an online randomization tool: http://www.graphpad.com/quickcalcs/index.cfm BLINDING (MASKING): This will be a double-blind study in which participants and those assessing the final outcomes will be blinded to group assignment. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): Regarding the pandemic crisis and our center capacity to hospitalize confirmed COVID-19 patients, a total of 80 patients was found to be logical to be randomized into two groups of 40- patients. TRIAL STATUS: Recruitment is ongoing. Recruitment began on 20/03/2020 and the date by which the recruitment is anticipated to be completed is 30/05/2020. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04360980, registered 24/04/2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol."],"journal":"Trials","authors":["Dalili, Nooshin","Kashefizadeh, Alireza","Nafar, Mohsen","Poorrezagholi, Fatemeh","Firouzan, Ahmad","Samadian, Fariba","Samavat, Shiva","Ziaie, Shadi","Fatemizadeh, Somayeh"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32503620","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1186/s13063-020-04455-3","keywords":["covid-19","colchicine","inflammation","oxidative stress","randomised controlled trial","protocol"],"locations":["Colchicine","Tehran","Iran","optimal","Iran","Colchicine","Colchicine"],"countries":["Iran, Islamic Republic of"],"countries_codes":["IRN|Iran, Islamic Republic of"],"e_drugs":["lopinavir-ritonavir drug combination","Digoxin","Creatinine","Colchicine"],"topics":["Treatment"],"weight":1,"_version_":1668892488385953792,"score":226.89915},{"pmid":32461554,"title":"Colchicine's effects on metabolic and inflammatory molecules in adults with obesity and metabolic syndrome: results from a pilot randomized controlled trial.","text":["Colchicine's effects on metabolic and inflammatory molecules in adults with obesity and metabolic syndrome: results from a pilot randomized controlled trial.","OBJECTIVE: Recent clinical trials have demonstrated that colchicine may have metabolic and cardiovascular and benefits in at-risk patients; however, the mechanisms through which colchicine may improve outcomes are still unclear. We sought to examine colchicine's effects on circulating inflammatory and metabolic molecules in adults with obesity and metabolic syndrome (MetS). METHODS: Blood samples were collected pre- and post-intervention during a double-blind randomized controlled trial in which 40 adults with obesity and MetS were randomized to colchicine 0.6 mg or placebo twice-daily for 3 months. Serum samples were analyzed for 1305 circulating factors using the SomaScan Platform. The Benjamini-Hochberg procedure was used to adjust the false discovery rate (FDR) for multiple testing. RESULTS: At baseline, age (48.0 +/- 13.8 vs. 44.7 +/- 10.3 years) and BMI (39.8 +/- 6.4 vs. 41.8 +/- 8.2 kg/m(2)) were not different between groups. After controlling for the FDR, 34 molecules were significantly changed by colchicine. Colchicine decreased concentrations of multiple inflammatory molecules, including C-reactive protein, interleukin 6, and resistin, in addition to vascular-related proteins (e.g., oxidized low-density lipoprotein receptor, phosphodiesterase 5A). Conversely, relative to placebo, colchicine significantly increased concentrations of eight molecules including secreted factors associated with metabolism and anti-thrombosis. CONCLUSIONS: In adults with obesity, colchicine significantly affected concentrations of proteins involved in the innate immune system, endothelial function and atherosclerosis, uncovering new mechanisms behind its cardiometabolic effects. Further research is warranted to investigate whether colchicine's IL-6 suppressive effects may be beneficial in COVID-19.","Int J Obes (Lond)","Demidowich, Andrew P","Levine, Jordan A","Apps, Richard","Cheung, Foo K","Chen, Jinguo","Fantoni, Giovanna","Patel, Tushar P","Yanovski, Jack A","32461554"],"abstract":["OBJECTIVE: Recent clinical trials have demonstrated that colchicine may have metabolic and cardiovascular and benefits in at-risk patients; however, the mechanisms through which colchicine may improve outcomes are still unclear. We sought to examine colchicine's effects on circulating inflammatory and metabolic molecules in adults with obesity and metabolic syndrome (MetS). METHODS: Blood samples were collected pre- and post-intervention during a double-blind randomized controlled trial in which 40 adults with obesity and MetS were randomized to colchicine 0.6 mg or placebo twice-daily for 3 months. Serum samples were analyzed for 1305 circulating factors using the SomaScan Platform. The Benjamini-Hochberg procedure was used to adjust the false discovery rate (FDR) for multiple testing. RESULTS: At baseline, age (48.0 +/- 13.8 vs. 44.7 +/- 10.3 years) and BMI (39.8 +/- 6.4 vs. 41.8 +/- 8.2 kg/m(2)) were not different between groups. After controlling for the FDR, 34 molecules were significantly changed by colchicine. Colchicine decreased concentrations of multiple inflammatory molecules, including C-reactive protein, interleukin 6, and resistin, in addition to vascular-related proteins (e.g., oxidized low-density lipoprotein receptor, phosphodiesterase 5A). Conversely, relative to placebo, colchicine significantly increased concentrations of eight molecules including secreted factors associated with metabolism and anti-thrombosis. CONCLUSIONS: In adults with obesity, colchicine significantly affected concentrations of proteins involved in the innate immune system, endothelial function and atherosclerosis, uncovering new mechanisms behind its cardiometabolic effects. Further research is warranted to investigate whether colchicine's IL-6 suppressive effects may be beneficial in COVID-19."],"journal":"Int J Obes (Lond)","authors":["Demidowich, Andrew P","Levine, Jordan A","Apps, Richard","Cheung, Foo K","Chen, Jinguo","Fantoni, Giovanna","Patel, Tushar P","Yanovski, Jack A"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32461554","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1038/s41366-020-0598-3","locations":["Benjamini-Hochberg","colchicine","Colchicine","colchicine","colchicine","Colchicine"],"e_drugs":["Colchicine"],"topics":["Treatment"],"weight":1,"_version_":1668079521554759681,"score":194.85298},{"pmid":32474885,"title":"Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.","text":["Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.","COVID-19 infection has a heterogenous disease course; it may be asymptomatic or causes only mild symptoms in the majority of the cases, while immunologic complications such as macrophage activation syndrome also known as secondary hemophagocytic lymphohistiocytosis, resulting in cytokine storm syndrome and acute respiratory distress syndrome, may also occur in some patients. According to current literature, impairment of SARS-CoV-2 clearance due to genetic and viral features, lower levels of interferons, increased neutrophil extracellular traps, and increased pyroptosis and probable other unknown mechanisms create a background for severe disease course complicated by macrophage activation syndrome and cytokine storm. Various genetic mutations may also constitute a risk factor for severe disease course and occurrence of cytokine storm in COVID-19. Once, immunologic complications like cytokine storm occur, anti-viral treatment alone is not enough and should be combined with appropriate anti-inflammatory treatment. Anti-rheumatic drugs, which are tried for managing immunologic complications of COVID-19 infection, will also be discussed including chloroquine, hydroxychloroquine, JAK inhibitors, IL-6 inhibitors, IL-1 inhibitors, anti-TNF-alpha agents, corticosteroids, intravenous immunoglobulin (IVIG), and colchicine. Early recognition and appropriate treatment of immunologic complications will decrease the morbidity and mortality in COVID-19 infection, which requires the collaboration of infectious disease, lung, and intensive care unit specialists with other experts such as immunologists, rheumatologists, and hematologists.","Clin Rheumatol","Soy, Mehmet","Keser, Gokhan","Atagunduz, Pamir","Tabak, Fehmi","Atagunduz, Isik","Kayhan, Servet","32474885"],"abstract":["COVID-19 infection has a heterogenous disease course; it may be asymptomatic or causes only mild symptoms in the majority of the cases, while immunologic complications such as macrophage activation syndrome also known as secondary hemophagocytic lymphohistiocytosis, resulting in cytokine storm syndrome and acute respiratory distress syndrome, may also occur in some patients. According to current literature, impairment of SARS-CoV-2 clearance due to genetic and viral features, lower levels of interferons, increased neutrophil extracellular traps, and increased pyroptosis and probable other unknown mechanisms create a background for severe disease course complicated by macrophage activation syndrome and cytokine storm. Various genetic mutations may also constitute a risk factor for severe disease course and occurrence of cytokine storm in COVID-19. Once, immunologic complications like cytokine storm occur, anti-viral treatment alone is not enough and should be combined with appropriate anti-inflammatory treatment. Anti-rheumatic drugs, which are tried for managing immunologic complications of COVID-19 infection, will also be discussed including chloroquine, hydroxychloroquine, JAK inhibitors, IL-6 inhibitors, IL-1 inhibitors, anti-TNF-alpha agents, corticosteroids, intravenous immunoglobulin (IVIG), and colchicine. Early recognition and appropriate treatment of immunologic complications will decrease the morbidity and mortality in COVID-19 infection, which requires the collaboration of infectious disease, lung, and intensive care unit specialists with other experts such as immunologists, rheumatologists, and hematologists."],"journal":"Clin Rheumatol","authors":["Soy, Mehmet","Keser, Gokhan","Atagunduz, Pamir","Tabak, Fehmi","Atagunduz, Isik","Kayhan, Servet"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32474885","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1007/s10067-020-05190-5","keywords":["covid-19","cytokine storm syndrome","hemophagocytic lymphohistiocytosis","macrophage activation syndrome"],"locations":["Cytokine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668341932687884289,"score":182.54417}]}